Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
Rhea-AI Summary
Fate Therapeutics (NASDAQ: FATE) said the FDA selected its off-the-shelf iPSC-derived anti-CD19 CAR T candidate FT819 for the CMC Development and Readiness Pilot (CDRP) program to support manufacturing readiness for SLE with lupus nephritis.
Selection and existing RMAT designation aim to accelerate CMC engagement and help align manufacturing readiness with a planned Phase 2 potentially registrational trial.
Positive
- FT819 selected for FDA CDRP program (one of ≤9 annual picks)
- Existing RMAT designation supports expedited regulatory interactions and potential accelerated approval
- Manufacturing focus: iPSC clonal master cell line enables scalable, off-the-shelf production
- Clinical impact: intended outpatient, same-day discharge dosing could broaden access
Negative
- None.
News Market Reaction – FATE
In the May 5 session, FATE gained 31.11%, reflecting a significant positive market reaction. Argus tracked a peak move of +31.4% during that session. Our momentum scanner triggered 49 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 5.2x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 04 | Conference presentations | Positive | +17.6% | ASGCT meeting presentations highlighting off-the-shelf CAR T pipeline data. |
| Apr 30 | Clinical data update | Positive | +0.8% | FT819 SLE clinical data presentation at CCR–East 2026 meeting. |
| Apr 16 | Preclinical data news | Positive | +6.2% | Preclinical FT839 dual‑CAR data for malignancies and autoimmune diseases. |
| Apr 09 | Investor conferences | Positive | +7.6% | Announcement of participation in multiple Q2 2026 investor conferences. |
| Apr 02 | Equity inducement grant | Neutral | -2.5% | RSU grant to a new employee under inducement equity plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, especially around FT819 and conference presentations, has often coincided with positive price reactions, suggesting sensitivity to clinical and visibility milestones.
Over the last two months, Fate Therapeutics has highlighted multiple developments around its off-the-shelf CAR T pipeline. News on FT819 SLE data and upcoming ASGCT and CCR–East presentations, along with AACR preclinical data for FT839, generally saw positive one-day moves, including +17.65% on May 4, 2026. Investor conferences in Q2 2026 also aligned with a gain of 7.63%. Only a small HR-related inducement grant on Apr 2 drew a negative reaction, indicating stronger interest in pipeline and visibility catalysts.
Key Terms
chemistry, manufacturing, and controls (cmc) regulatory
development and readiness pilot (cdrp) program regulatory
regenerative medicine advanced therapy (rmat) designation regulatory
breakthrough therapy designation (btd) regulatory
type b meetings regulatory
chimeric antigen receptor (car) t-cell medical
induced pluripotent stem cell (ipsc) medical
systemic lupus erythematosus (sle) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines
Current Regenerative Medicine Advanced Therapy (RMAT) designation and CDRP participation provide opportunity for expedited regulatory pathway and advancement of FT819 Phase 2 potentially registrational clinical trial in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis
SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has selected FT819 for participation in the Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program for treatment of moderate to severe systemic lupus erythematosus (SLE).
The FDA CDRP Program is a highly selective initiative, with no more than nine proposals accepted annually across the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). The program is designed for investigational therapies intended to diagnose, treat, or prevent serious diseases with unmet medical need and is limited to sponsors that have received Regenerative Medicine Advanced Therapy (RMAT) or Breakthrough Therapy Designation (BTD). Participation in the CDRP Program is intended to accelerate product development by enabling enhanced, product-specific FDA engagement on CMC related manners. The program provides increased communication with the FDA, including additional CMC-focused Type B meetings to help clarify development strategies, address key questions, and support manufacturing readiness, ultimately helping to ensure that the CMC readiness for marketing keeps pace with expected faster clinical timelines, so that product approvals are not held up by CMC bottlenecks.
FT819 is an off-the-shelf anti-CD19 chimeric antigen receptor (CAR) T-cell therapy candidate currently under investigation for patients with various B-cell related autoimmune disorders. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, a precisely engineered clonal master induced pluripotent stem cell (iPSC) line serves as the starting cell source to manufacture FT819, overcoming numerous limitations associated with patient- and donor-sourced CAR T-cell therapies. Under the FT819 Phase 1 autoimmune basket clinical protocol, broad patient accessibility is enabled, especially in underserved regions, with on-demand availability of drug product and outpatient treatment with same-day discharge. FT819 previously received RMAT designation from the FDA for the treatment of moderate-to-severe SLE. The RMAT designation was granted based on preliminary clinical evidence demonstrating the potential of FT819 to address significant unmet need in patients with SLE. The RMAT designation provides the Company with benefits including FDA guidance on efficient development, alignment on CMC readiness, and the potential for accelerated approval.
"The selection of FT819 into the FDA's CDRP Program is a powerful validation of the science we have built at Fate Therapeutics and a meaningful step forward in our path to commercialization," said Bob Valamehr, Ph.D., MBA, President and Chief Executive Officer of Fate Therapeutics. "The selection into the CDRP program, combined with our RMAT designation, is intended to accelerate our manufacturing readiness as we embark on our Phase 2 potentially registrational clinical trial in SLE. FT819 is designed to be administered on an outpatient basis with same-day discharge, and our off-the-shelf approach enables on-demand availability across community hospitals and in outpatient settings, making transformative CAR T-cell therapy accessible to patients who have historically faced significant barriers to treatment. We are deeply committed to ensuring that this innovation does not remain confined to specialized centers, and today's announcement brings us one step closer to delivering on that promise."
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the potential benefits of FT819 based on preliminary data, the anticipated benefits of RMAT designation and participation in the CDRP program, the ability of the Company to expedite commercial manufacturing readiness of FT819, the advancement of and plans related to the Company's product candidates and clinical studies, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, the initiation and continuation of enrollment in the Company’s clinical trials, the initiation of additional clinical trials, including in new indications, the availability of data from the Company’s clinical trials and the Company’s plans to provide updates on its clinical trials, the therapeutic and market potential of the Company’s research and development programs and product candidates, the Company’s clinical and product development strategy, and the Company’s progress and plans relating to, and the anticipated timing and outcome of, interactions with the FDA and other regulatory authorities, including its expectations relating to alignment with regulatory authorities on potential registrational pathways for FT819. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, risks relating to regulatory interactions and the outcome of such interactions, and the risk that the Company may not obtain adequate financing to fund its planned clinical trials and other expenses. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Contact:
Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com
